Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Luye Pharma Completes US Phase II Trial of Cardiovascular TCM

publication date: Feb 18, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Luye Pharma Group reported its Xuezhikang drug, a TCM used to lower cholesterol, proved effective in a US Phase II clinical trial. According to the company, the drug “significantly” lowered low-density lipoprotein cholesterol while elevating beneficial high-density lipoprotein cholesterol. The company did not disclose specific data from the trial. Xuezhikang is the only TCM included in the National Basic List as a treatment for blood lipids. More details....

Stock Symbol: (SGX: A61)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Event Updates
Greg Scott will be attending and speaking at these events:
 
 
 
Hope to see you there!
 
ChinaBio® Events
More events coming soon...

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors